Thanks Stephen V Liu, MD for the shoutout on our 🚨Pub Alert 🚨in JTO & JTO CRR #JTOCRR
Here’s the key 🔑 takeaways:
1️⃣ EGFR-RAD51 fusions are rare
2️⃣ osimertinib = effective/durable
3️⃣ know the coverage of #NGS panels
4️⃣ precision medicine changes lives
#LCSM #liquidbiopsy
#WCLC23 The editorial team can’t wait to meet you all! Stop by the Journals booth at A137 JTO & JTO CRR IASLC #JTO #JTO CRR Oncology Advance
Great to see this important and timely study on the genomic landscape of lung cancer in Ireland. Findings like these are crucial for helping us understand our population. Great work Jarushka Naidoo and colleagues! #JTOCRR JTO & JTO CRR
Report on a pilot intervention to inform women undergoing screening mammography about lung cancer screening in #JTOCRR JTO & JTO CRR. Patients were responsive to learning about dual screening - important efforts from Drs. Lye-Yeng Wong MD Leah Backhus MD MPH FACS
jtocrr.org/article/S2666-…
Stephen V Liu, MD Captivating case report in the #JTOCRR , highlighting the complexity of treating #KRAS G12C NSCLC with evolving therapeutic agents. Sotorasib showing promise post chemo-IO but with notable hepatotoxicity challenges reinforces the need for tailored treatments based on patient…
Stephen V Liu, MD Lizza Hendriks Nice findings by Dr. Lizza Hendriks and colleagues in #JTOCRR , shedding light on the complex relationship between osimertinib plasma concentration and CNS control in #EGFR NSCLC patients. This research underscores the importance of exploring multiple avenues for optimizing…
Stephen V Liu, MD JTO & JTO CRR As a scientist with a focus on biomedical research, I find the case highlighted in #JTOCRR to be a crucial reminder of the importance of monitoring for pneumonitis/interstitial lung disease when using adjuvant osimertinib in #EGFR NSCLC patients. The capacity for early…
#TobaccoControl Impacts Everyone in Respiratory Medicine, #JTOCRR Editor Says ilcn.org/tobacco-contro… JTO & JTO CRR IASLC